1Department of Pharmaceutical, Chemistry and Quality Control, Faculty of Pharmacy, Damascus University, Damascus, Syria
2Department of Pharmaceutical Chemistry and Quality Control, Faculty of pharmacy, Arab International University, Ghabaghib, Daraa, Syria
Canagliflozin is a newly approved drug for type II diabetes mellitus, in the present work, a strategy based on high performance liquid chromatography combined with mass spectrometry (HPLC-UV/MS) method was proposed to systematically characterize the in vivo metabolites of canagliflozin in Rats. After oral administration of Canagliflozin to rats in a single dose of 3mg/kg, the rat plasma, urine, feces samples were collected and used in order to to determine metabolites. As a result of that and besides the parent drug, a total of 12 metabolites of canagliflozin were detected and identified.it was indicated that the metabolic pathways of canagliflozin in rats included: oxidation (as a main rout), glucuronation, and hydroxylation The result could provide valuable information regarding the metabolism of canagliflozin in rats, which contribute to better understanding of its action mechanism.
Canagliflozin, metabolites, diabetes, HPLC-UV/MS, sodium glucose co-transporter 2 inhibitor
